Mostrar el registro sencillo del ítem
dc.contributor.author | Rondy, Marc | |
dc.contributor.author | Kissling, Esther | |
dc.contributor.author | Emborg, Hanne-Dorthe | |
dc.contributor.author | Gherasim, Alin Manuel | |
dc.contributor.author | Pebody, Richard | |
dc.contributor.author | Trebbien, Ramona | |
dc.contributor.author | Pozo Sanchez, Francisco | |
dc.contributor.author | Larrauri, Amparo | |
dc.contributor.author | McMenamin, Jim | |
dc.contributor.author | Valenciano, Marta | |
dc.contributor.author | I-MOVE/I-MOVE+ group | |
dc.contributor.author | Delgado-Sanz, Concepcion | |
dc.contributor.author | Oliva Dominguez, Jesus Angel | |
dc.contributor.author | Casas Flecha, Inmaculada | |
dc.date.accessioned | 2020-01-30T09:32:12Z | |
dc.date.available | 2020-01-30T09:32:12Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Euro Surveill. 2018 Mar;23(9):18-00086. | es_ES |
dc.identifier.issn | 1560-7917 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/8992 | |
dc.description.abstract | Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates. | es_ES |
dc.description.sponsorship | Funding: The five studies have received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446 to conduct the study in individuals aged 65 years or more. ECDC has contributed to fund some study sites of the EU-PC study under the Framework contract No ECDC/2014/026 for the individuals aged less than 65 years. All study teams are very grateful to all patients, general practitioners, paediatricians, hospital teams, laboratory teams, regional epidemiologists who have contributed to the studies. We acknowledge the authors, originating and submitting laboratories of the sequences from GISAID’s EpiFlu Database used for this study. All submitters of data may be contacted directly via the GISAID website www.gisaid.org | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | European Centre for Disease Prevention and Control (ECDC) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Europe | es_ES |
dc.subject | Case control study | es_ES |
dc.subject | Influenza | es_ES |
dc.subject | Influenza vaccination | es_ES |
dc.subject | Influenza vaccine effectiveness | es_ES |
dc.subject | Multicentre study | es_ES |
dc.subject.mesh | Adolescent | es_ES |
dc.subject.mesh | Adult | es_ES |
dc.subject.mesh | Aged | es_ES |
dc.subject.mesh | Child | es_ES |
dc.subject.mesh | Child, Preschool | es_ES |
dc.subject.mesh | Europe | es_ES |
dc.subject.mesh | European Union | es_ES |
dc.subject.mesh | Female | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Infant | es_ES |
dc.subject.mesh | Infant, Newborn | es_ES |
dc.subject.mesh | Influenza A Virus, H1N1 Subtype | es_ES |
dc.subject.mesh | Influenza A Virus, H3N2 Subtype | es_ES |
dc.subject.mesh | Influenza B virus | es_ES |
dc.subject.mesh | Influenza Vaccines | es_ES |
dc.subject.mesh | Influenza, Human | es_ES |
dc.subject.mesh | Male | es_ES |
dc.subject.mesh | Middle Aged | es_ES |
dc.subject.mesh | Pandemics | es_ES |
dc.subject.mesh | Treatment Outcome | es_ES |
dc.subject.mesh | Vaccination | es_ES |
dc.subject.mesh | Seasons | es_ES |
dc.title | Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 29510782 | es_ES |
dc.format.volume | 23 | es_ES |
dc.format.number | 9 | es_ES |
dc.identifier.doi | 10.2807/1560-7917.ES.2018.23.9.18-00086 | es_ES |
dc.contributor.funder | Unión Europea | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1560-7917 | es_ES |
dc.relation.publisherversion | https://doi.org/10.2807/1560-7917.ES.2018.23.9.18-00086 | es_ES |
dc.identifier.journal | Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Epidemiología | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | Horizon 2020 research and innovation programme under grant agreement No 634446 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/ECDC/2014/026 | es_ES |
dc.rights.accessRights | open access | es_ES |